Abstract
AbstractNext generation sequencing (NGS) is a trending new standard for genotypic HIV-1 drug resistance (HIVDR) testing. Many NGS HIVDR data analysis pipelines have been independently developed, each with variable outputs and data management protocols. Standardization of such analytical methods and comparison of available pipelines are lacking, yet may impact subsequent HIVDR interpretation and other downstream applications. Here we compared the performance of five NGS HIVDR pipelines using proficiency panel samples from NIAID Virology Quality Assurance (VQA) program. Ten VQA panel specimens were genotyped by each of six international laboratories using their own in-house NGS assays. Raw NGS data were then processed using each of the five different pipelines including HyDRA, MiCall, PASeq, Hivmmer and DEEPGEN. All pipelines detected amino acid variants (AAVs) at full range of frequencies (1~100%) and demonstrated good linearity as compared to the reference frequency values. While the sensitivity in detecting low abundance AAVs, with frequencies between 1~20%, is less a concern for all pipelines, their specificity dramatically decreased at AAV frequencies <2%, suggesting that 2% threshold may be a more reliable reporting threshold for ensured specificity in AAV calling and reporting. More variations were observed among the pipelines when low abundance AAVs are concerned, likely due to differences in their NGS read quality control strategies. Findings from this study highlight the need for standardized strategies for NGS HIVDR data analysis, especially for the detection of minority HIVDR variants.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. WHO. World Health Organization Global Strategy For The Surveillance And Monitoring Of HIV Drug Resistance. HIV/AIDS Programme. Available at: http:/www.who.int/hiv/pub/drugresistance/drug_resistance_strategy/en/ (2012).
2. Bennett, D. E. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr. Opin. Infect. Dis. 19, 607–614 (2006).
3. Hamers, R. L. et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study. Lancet Infect. Dis. 12, 307–317 (2012).
4. Boender, T. S. et al. Pretreatment HIV drug resistance increases regimen switches in sub-saharan Africa. Clin. Infect. Dis. 61, 1749–1758 (2015).
5. Pinoges, L. et al. Risk Factors and Mortality Associated With Resistance to First-Line Antiretroviral Therapy. JAIDS J. Acquir. Immune Defic. Syndr. 68, 527–535 (2015).
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献